[1]
|
Liang, Y., Zhang, H., Song, X. and Yang, Q. (2020) Metastatic Heterogeneity of Breast Cancer: Molecular Mechanism and Potential Therapeutic Targets. Seminars in Cancer Biology, 60, 14-27.
https://doi.org/10.1016/j.semcancer.2019.08.012
|
[2]
|
Hart, C.D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L. and Di Leo, A. (2015) Challenges in the Management of Advanced, ER-Positive, HER2-Negative Breast Cancer. Nature Reviews Clinical Oncology, 12, 541-552.
https://doi.org/10.1038/nrclinonc.2015.99
|
[3]
|
Finn, R.S., Martin, M., Rugo, H.S., et al. (2016) Palbociclib and Letrozole in Advanced Breast Cancer. The New England Journal of Medicine, 375, 1925-1936. https://doi.org/10.1056/NEJMoa1607303
|
[4]
|
Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., et al. (2016) Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. The New England Journal of Medicine, 375, 1738-1748.
https://doi.org/10.1056/NEJMoa1609709
|
[5]
|
Goetz, M.P., Toi, M., Campone, M., et al. (2017) MONARCH 3: Abemaciclib as Initial Therapy for Advanced Breast Cancer. Journal of Clinical Oncology, 35, 3638-3646. https://doi.org/10.1200/JCO.2017.75.6155
|
[6]
|
Cristofanilli, M., Turner, N.C., Bondarenko, I., et al. (2016) Fulvestrant plus Palbociclib versus Fulvestrant plus Placebo for Treatment of Hormone-Receptor-Positive, HER2-Negative Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy (PALOMA-3): Final Analysis of the Multicentre, Double-Blind, Phase 3 Randomised Controlled Trial. The Lancet Oncology, 17, 425-439. https://doi.org/10.1016/S1470-2045(15)00613-0
|
[7]
|
Wu, Y., Zhang, Y., Pi, H. and Sheng, Y. (2020) Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer. Cancer Management and Research, 12, 3477-3487. https://doi.org/10.2147/CMAR.S250632
|
[8]
|
Narasimha, A.M., Kaulich, M., Shapiro, G.S., Choi, Y.J., Sicinski, P. and Dowdy, S.F. (2014) Cyclin D Activates the Rb Tumor Suppressor by Mono-Phosphorylation. Elife, 3, 2872. https://doi.org/10.7554/eLife.02872
|
[9]
|
Harbour, J.W., Luo, R.X., Dei Santi, A., Postigo, A.A. and Dean, D.C. (1999) Cdk Phosphorylation Triggers Sequential Intramolecular Interactions That Progressively Block Rb Functions as Cells Move through G1. Cell, 98, 859-869.
https://doi.org/10.1016/S0092-8674(00)81519-6
|
[10]
|
Hiebert, S.W., Chellappan, S.P., Horowitz, J.M. and Nevins, J.R. (1992) The Interaction of RB with E2F Coincides with an Inhibition of the Transcriptional Activity of E2F. Genes & Development, 6, 177-185.
https://doi.org/10.1101/gad.6.2.177
|
[11]
|
Weintraub, S.J., Chow, K.N.B., Luo, R.X., Zhang, S.H., He, S. and Dean, D.C. (1995) Mechanism of Active Transcriptional Repression by the Retinoblastoma Protein. Nature, 375, 812-816. https://doi.org/10.1038/375812a0
|
[12]
|
Mayer, E.L. (2015) Targeting Breast Cancer with CDK Inhibitors. Current Oncology Reports, 17, 443.
https://doi.org/10.1007/s11912-015-0443-3
|
[13]
|
Malumbres, M. and Barbacid, M. (2009) Cell Cycle, CDKs and Cancer: A Changing Paradigm. Nature Reviews Cancer, 9, 153-166. https://doi.org/10.1038/nrc2602
|
[14]
|
Taneja, P., Maglic, D., Kai, F., et al. (2010) Classical and Novel Prognostic Markers for Breast Cancer and Their Clinical Significance. Clinical Medicine Insights: Oncology, 4, 15-34. https://doi.org/10.4137/CMO.S4773
|
[15]
|
Musgrove, E.A., Caldon, C.E., Barraclough, J., Stone, A. and Sutherland, R.L. (2011) Cyclin D as a Therapeutic Target in Cancer. Nature Reviews Cancer, 11, 558-572. https://doi.org/10.1038/nrc3090
|
[16]
|
Musgrove, E.A., Lee, C.S., Buckley, M.F. and Sutherland, R.L. (1994) Cyclin D1 Induction in Breast Cancer Cells Shortens G1 and Is Sufficient for Cells Arrested in G1 to Complete the Cell Cycle. Proceedings of the National Academy of Sciences of the United States of America, 91, 8022-8026. https://doi.org/10.1073/pnas.91.17.8022
|
[17]
|
Wang, T.C., Cardiff, R.D., Zukerberg, L., Lees, E., Arnold, A. and Schmidt, E.V. (1994) Mammary Hyperplasia and Carcinoma in MMTV-Cyclin D1 Transgenic Mice. Nature, 369, 669-671. https://doi.org/10.1038/369669a0
|
[18]
|
Jares, P., Colomer, D. and Campo, E. (2007) Genetic and Molecular Pathogenesis of Mantle Cell Lymphoma: Perspectives for New Targeted Therapeutics. Nature Reviews Cancer, 7, 750-762. https://doi.org/10.1038/nrc2230
|
[19]
|
Roy, P.G. and Thompson, A.M. (2006) Cyclin D1 and Breast Cancer. Breast, 15, 718-727.
https://doi.org/10.1016/j.breast.2006.02.005
|
[20]
|
An, H.X., Beckmann, M.W., Reifenberger, G., Bender, H.G. and Niederacher, D. (1999) Gene Amplification and Overexpression of CDK4 in Sporadic Breast Carcinomas Is Associated with High Tumor Cell Proliferation. The American Journal of Pathology, 154, 113-118. https://doi.org/10.1016/S0002-9440(10)65257-1
|
[21]
|
Timmermann, S., Hinds, P.W. and Münger, K. (1997) Elevated Activity of Cyclin-Dependent Kinase 6 in Human Squamous Cell Carcinoma Lines. Cell Growth & Differentiation, 8, 361-370.
|
[22]
|
Wang, H., Nicolay, B.N., Chick, J.M., et al. (2017) The Metabolic Function of Cyclin D3-CDK6 Kinase in Cancer Cell Survival. Nature, 546, 426-430. https://doi.org/10.1038/nature22797
|
[23]
|
Pandey, K., An, H.J., Kim, S.K., et al. (2019) Molecular Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer: A Review. International Journal of Cancer, 145, 1179-1188. https://doi.org/10.1002/ijc.32020
|
[24]
|
Wiedemeyer, W.R., Dunn, I.F., Quayle, S.N., et al. (2010) Pattern of Retinoblastoma Pathway Inactivation Dictates Response to CDK4/6 Inhibition in GBM. Proceedings of the National Academy of Sciences of the United States of America, 107, 11501-11506. https://doi.org/10.1073/pnas.1001613107
|
[25]
|
Malorni, L., Piazza, S., Ciani, Y., et al. (2016) A Gene Expression Signature of Retinoblastoma Loss-of-Function Is a Predictive Biomarker of Resistance to Palbociclib in Breast Cancer Cell Lines and Is Prognostic in Patients with ER Positive Early Breast Cancer. Oncotarget, 7, 68012-68022. https://doi.org/10.18632/oncotarget.12010
|
[26]
|
Condorelli, R., Spring, L., O’Shaughnessy, J., et al. (2018) Polyclonal RB1 Mutations and Acquired Resistance to CDK 4/6 Inhibitors in Patients with Metastatic Breast Cancer. Annals of Oncology, 29, 640-645.
https://doi.org/10.1093/annonc/mdx784
|
[27]
|
Obeyesekere, M.N., Herbert, J.R. and Zimmerman, S.O. (1995) A Model of the G1 Phase of the Cell Cycle Incorporating Cyclin E/cdk2 Complex and Retinoblastoma Protein. Oncogene, 11, 1199-1205.
|
[28]
|
Knudsen, E.S., Shapiro, G.I. and Keyomarsi, K. (2020) Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. American Society of Clinical Oncology Educational Book, Vol. 40, 115-126. https://doi.org/10.1200/EDBK_281085
|
[29]
|
Lapenna, S. and Giordano, A. (2009) Cell Cycle Kinases as Therapeutic Targets for Cancer. Nature Reviews Drug Discovery, 8, 547-566. https://doi.org/10.1038/nrd2907
|
[30]
|
Choi, Y.J. and Anders, L. (2014) Signaling through Cyclin D-Dependent Kinases. Oncogene, 33, 1890-1903.
https://doi.org/10.1038/onc.2013.137
|
[31]
|
Siebert, R., Willers, C.P. and Opalka, B. (1996) Role of the Cyclin-Dependent Kinase 4 and 6 Inhibitor Gene Family p15, p16, p18 and p19 in Leukemia and Lymphoma. Leukemia & Lymphoma, 23, 505-520.
https://doi.org/10.3109/10428199609054859
|
[32]
|
Serrano, M., Hannon, G.J. and Beach, D. (1993) A New Regulatory Motif in Cell-Cycle Control Causing Specific Inhibition of Cyclin D/CDK4. Nature, 366, 704-707. https://doi.org/10.1038/366704a0
|
[33]
|
Russo, A.A., Tong, L., Lee, J.O., Jeffrey, P.D. and Pavletich, N.P. (1998) Structural Basis for Inhibition of the Cyclin-Dependent Kinase Cdk6 by the Tumour Suppressor p16INK4a. Nature, 395, 237-243.
https://doi.org/10.1038/26155
|
[34]
|
Liu, Y., Zhong, X., Wan, S., et al. (2014) p16(INK4a) Expression in Retinoblastoma: A Marker of Differentiation Grade. Diagnostic Pathology, 9, 180. https://doi.org/10.1186/s13000-014-0180-1
|
[35]
|
Dean, J.L., McClendon, A.K., Hickey, T.E., et al. (2012) Therapeutic Response to CDK4/6 Inhibition in Breast Cancer Defined by ex Vivo Analyses of Human Tumors. Cell Cycle, 11, 2756-2761. https://doi.org/10.4161/cc.21195
|
[36]
|
Jagarlamudi, K.K. and Shaw, M. (2018) Thymidine Kinase 1 as a Tumor Biomarker: Technical Advances Offer New Potential to an Old Biomarker. Biomarkers in Medicine, 12, 1035-1048. https://doi.org/10.2217/bmm-2018-0157
|
[37]
|
Topolcan, O. and Holubec, L. (2008) The Role of Thymidine Kinase in Cancer Diseases. Expert Opinion on Medical Diagnostics, 2, 129-141. https://doi.org/10.1517/17530059.2.2.129
|
[38]
|
Broët, P., Romain, S., Daver, A., et al. (2001) Thymidine Kinase as a Proliferative Marker: Clinical Relevance in 1,692 Primary Breast Cancer Patients. Journal of Clinical Oncology, 19, 2778-2787.
https://doi.org/10.1200/JCO.2001.19.11.2778
|
[39]
|
Romain, S., Spyratos, F., Descotes, F., et al. (2000) Prognostic of DNA-Synthesizing Enzyme Activities (Thymidine Kinase and Thymidylate Synthase) in 908 T1-T2, N0-N1, M0 Breast Cancers: A Retrospective Multicenter Study. International Journal of Cancer, 87, 860-868.
https://doi.org/10.1002/1097-0215(20000915)87:6<860::AID-IJC16>3.0.CO;2-Y
|
[40]
|
Bonechi, M., Galardi, F., Biagioni, C., et al. (2018) Plasma Thymidine Kinase-1 Activity Predicts Outcome in Patients with Hormone Receptor Positive and HER2 Negative Metastatic Breast Cancer Treated with Endocrine Therapy. Oncotarget, 9, 16389-16399. https://doi.org/10.18632/oncotarget.24700
|
[41]
|
Del Re, M., Bertolini, I., Crucitta, S., et al. (2019) Overexpression of TK1 and CDK9 in Plasma-Derived Exosomes Is Associated with Clinical Resistance to CDK4/6 Inhibitors in Metastatic Breast Cancer Patients. Breast Cancer Research and Treatment, 178, 57-62. https://doi.org/10.1007/s10549-019-05365-y
|
[42]
|
Li, Z., Razavi, P., Li, Q., et al. (2018) Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway. Cancer Cell, 34, 893-905. https://doi.org/10.1016/j.ccell.2018.11.006
|
[43]
|
Turner, N., Pearson, A., Sharpe, R., et al. (2010) FGFR1 Amplification Drives Endocrine Therapy Resistance and Is a Therapeutic Target in Breast Cancer. Cancer Research, 70, 2085-2094.
https://doi.org/10.1158/0008-5472.CAN-09-3746
|
[44]
|
Costa, C., Wang, Y., Ly, A., et al. (2020) PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer. Cancer Discovery, 10, 72-85. https://doi.org/10.1158/2159-8290.CD-18-0830
|
[45]
|
Michaloglou, C., Crafter, C., Siersbaek, R., et al. (2018) Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-Term Growth Inhibition in Estrogen Receptor-Positive Breast Cancer. Molecular Cancer Therapeutics, 17, 908-920. https://doi.org/10.1158/1535-7163.MCT-17-0537
|
[46]
|
Migliaccio, I., Bonechi, M., McCartney, A., et al. (2021) CDK4/6 Inhibitors: A Focus on Biomarkers of Response and Post-Treatment Therapeutic Strategies in Hormone Receptor-Positive HER2-Negative Breast Cancer. Cancer Treatment Reviews, 93, 102-136. https://doi.org/10.1016/j.ctrv.2020.102136
|
[47]
|
Turner, N.C., Liu, Y., Zhu, Z., et al. (2019) Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer [Published Correction Appears in Journal of Clinical Oncology. 2019 Nov 1; 37(31): 2956]. Journal of Clinical Oncology, 37, 1169-1178. https://doi.org/10.1200/JCO.18.00925
|
[48]
|
Finn, R.S., Liu, Y., Zhu, Z., et al. (2020) Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research, 26, 110-121. https://doi.org/10.1158/1078-0432.CCR-19-0751
|
[49]
|
Finn, R.S., Crown, J.P., Ettl, J., et al. (2016) Efficacy and Safety of Palbociclib in Combination with Letrozole as First-Line Treatment of ER-Positive, HER2-Negative, Advanced Breast Cancer: Expanded Analyses of Subgroups from the Randomized Pivotal Trial PALOMA-1/TRIO-18. Breast Cancer Research, 18, 67.
https://doi.org/10.1186/s13058-016-0721-5
|